UY37067A - Método para la preparación de isótopos - Google Patents
Método para la preparación de isótoposInfo
- Publication number
- UY37067A UY37067A UY0001037067A UY37067A UY37067A UY 37067 A UY37067 A UY 37067A UY 0001037067 A UY0001037067 A UY 0001037067A UY 37067 A UY37067 A UY 37067A UY 37067 A UY37067 A UY 37067A
- Authority
- UY
- Uruguay
- Prior art keywords
- solution
- exchange resin
- anion exchange
- strong base
- base anion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/04—Processes using organic exchangers
- B01J41/05—Processes using organic exchangers in the strongly basic form
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona un método para la purificación de 227Th a partir de una mezcla que comprende 227Th y 223Ra, comprendiendo dicho método: i) preparar una primera solución que comprende una mezcla de iones 227Th y 223Ra disueltos en una solución acuosa del primer ácido mineral; ii) cargar dicha primera solución en una resina de intercambio aniónico de base fuerte; iii) eluir 223Ra de dicha resina de intercambio aniónico de base fuerte utilizando un segundo ácido mineral en una solución acuosa; iv) enjuagar opcionalmente dicha resina de intercambio aniónico de base fuerte utilizando un primer medio acuoso; v) eluir 227Th de dicha resina de intercambio aniónico de base fuerte utilizando un tercer ácido mineral en una solución acuosa generando así una segunda solución que comprende 227Th. La invención proporciona adicionalmente una solución de 227Th purificado, una formulación farmacéutica correspondiente y métodos para el tratamiento de enfermedades neoplásicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1600153.9A GB201600153D0 (en) | 2016-01-05 | 2016-01-05 | Isotope preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY37067A true UY37067A (es) | 2017-08-31 |
Family
ID=55406714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001037067A UY37067A (es) | 2016-01-05 | 2017-01-05 | Método para la preparación de isótopos |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10702613B2 (es) |
| EP (1) | EP3400085A1 (es) |
| JP (1) | JP6901498B2 (es) |
| CN (1) | CN108472556B (es) |
| AR (1) | AR107300A1 (es) |
| CA (1) | CA3010191A1 (es) |
| GB (1) | GB201600153D0 (es) |
| TW (1) | TW201726180A (es) |
| UY (1) | UY37067A (es) |
| WO (1) | WO2017118592A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3682959A1 (en) * | 2019-01-16 | 2020-07-22 | Sck Cen | Purification of actinium |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4390517A (en) * | 1979-12-19 | 1983-06-28 | New England Nuclear Corporation | Method, composition and kit for stabilizing radiolabeled compounds |
| US5809394A (en) | 1996-12-13 | 1998-09-15 | Battelle Memorial Institute | Methods of separating short half-life radionuclides from a mixture of radionuclides |
| NO310544B1 (no) * | 1999-01-04 | 2001-07-23 | Algeta As | Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben |
| US20060228297A1 (en) * | 2003-04-15 | 2006-10-12 | Roy Larsen | Thorium-227 for use in radiotherapy of soft tissue disease |
| GB0308731D0 (en) * | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| EP1617876B1 (en) * | 2003-04-15 | 2014-05-14 | Algeta AS | Thorium-227 for use in radiotherapy of soft tissue disease |
| CA2782608A1 (en) * | 2009-12-07 | 2011-10-13 | Medi-Physics, Inc. | Multiple generator elution system |
| GB201002508D0 (en) * | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201007353D0 (en) * | 2010-04-30 | 2010-06-16 | Algeta Asa | Method |
| GB201007354D0 (en) * | 2010-04-30 | 2010-06-16 | Algeta Asa | Method |
-
2016
- 2016-01-05 GB GBGB1600153.9A patent/GB201600153D0/en not_active Ceased
- 2016-12-29 EP EP16826752.4A patent/EP3400085A1/en not_active Withdrawn
- 2016-12-29 CN CN201680077965.8A patent/CN108472556B/zh active Active
- 2016-12-29 JP JP2018553303A patent/JP6901498B2/ja active Active
- 2016-12-29 US US16/066,600 patent/US10702613B2/en not_active Expired - Fee Related
- 2016-12-29 WO PCT/EP2016/082837 patent/WO2017118592A1/en active Application Filing
- 2016-12-29 CA CA3010191A patent/CA3010191A1/en active Pending
-
2017
- 2017-01-05 TW TW106100235A patent/TW201726180A/zh unknown
- 2017-01-05 UY UY0001037067A patent/UY37067A/es not_active Application Discontinuation
- 2017-01-05 AR ARP170100024A patent/AR107300A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017118592A1 (en) | 2017-07-13 |
| US10702613B2 (en) | 2020-07-07 |
| AR107300A1 (es) | 2018-04-18 |
| CA3010191A1 (en) | 2017-07-13 |
| JP6901498B2 (ja) | 2021-07-14 |
| TW201726180A (zh) | 2017-08-01 |
| CN108472556B (zh) | 2022-08-02 |
| GB201600153D0 (en) | 2016-02-17 |
| US20190015530A1 (en) | 2019-01-17 |
| CN108472556A (zh) | 2018-08-31 |
| EP3400085A1 (en) | 2018-11-14 |
| JP2019510809A (ja) | 2019-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000081A (es) | Modulador del regulador de conductancia de transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| BR112018068565A2 (pt) | combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos | |
| BR112017016019A2 (pt) | método para tratamento de câncer, artigo para fabricação, e, kit. | |
| CL2019001447A1 (es) | Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos. | |
| AR112269A1 (es) | Una preparación que comprende gránulos finos o gránulos | |
| BR112015025711A2 (pt) | terapia de combinação com ibrutinibe | |
| NI201700076A (es) | Complejos radiofarmacéuticos | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| CL2021000207A1 (es) | Nuevas proteínas de fusión específicas para cd137 y pd-l1 | |
| BR112017007063A2 (pt) | ?composições e métodos para o tratamento de insônia? | |
| AR104060A1 (es) | Partículas de n-(5-ciano-4-((2-metoxietil)amino)piridin-2-il)-7-formil-6-((4-metil-2-oxopiperazin-1-il)metil)-3,4-dihidro-1,8-naftiridina-1(2h)-carboxamida | |
| SV2017005412A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| UY36920A (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral | |
| BR112018017067A2 (pt) | pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inibidores de pde1 | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| UY37064A (es) | Método de purificación | |
| BR112017020818A2 (pt) | composto, uso de um composto, método, e, medicamento | |
| MX2015013155A (es) | Formulaciones farmaceuticas de la familia de la tetrandrina y metodo. | |
| CU20190042A7 (es) | Compuestos derivados de naftiridinona | |
| CL2019003463A1 (es) | Composición farmacéutica y forma de dosis farmacéutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenzamida, proceso para su preparación, métodos para tratamiento y usos de estas. | |
| UY37067A (es) | Método para la preparación de isótopos | |
| BR112017001165A2 (pt) | terapia combinada | |
| AR107299A1 (es) | Método para la preparación de isótopos | |
| UY37065A (es) | Método de purificación | |
| CU20180110A7 (es) | Una composición que comprende pic para el tratamiento del cáncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20230601 |